When paired with biotech, AI can accelerate breakthroughs that would normally take decades, if not millions of years, to develop—
the latest episode of the I am BIO Podcast explores a few examples.
Zeroing in on pathogens: Genetic Leap uses AI to find the optimal RNA position for a drug to target, predict the structure of that position, AND find a molecule to fit, says CEO Bertrand Adanve. The company is targeting MYC proteins—which contribute to many types of cancer—and working to develop other small-molecule drugs rapidly.
Guiding peptides:Peptilogics is using AI to develop peptides to fight rare diseases, cancer, and other conditions, says CTO Nick Nystrom.
Computers mapped the human genome before AI—but now, we have better tools to take advantage of it, says BAKX Therapeutics CEO Sree Kant. Combining genetic data, increased computational power, and a “precompetitive” approach to sharing data can drive a “tsunami” of medical advances.
The power of data: Gathering the data AI needs, Triplebar enables rapid developments, says CEO Maria Cho. “Because we are looking at the evolutionary design in the lab, we can actually then run evolution at hyper speed.”
The big picture: “It’s exciting to think about what we can achieve through the convergence of biotechnology and AI. Human ingenuity has taken us far, and AI and machine learning will take us even farther, faster,” concludes podcast host BIO CEO Rachel King.
Listen: The new season of the I am BIO Podcast is available via Apple, Google, Spotify, or wherever you get your podcasts, with new episodes released every other Tuesday.
More Health News:
The Wall Street Journal: Veterans Affairs to be first major insurer to cover Alzheimer’s drug Leqembi
“An estimated 167,954 veterans receiving care through the VA have Alzheimer’s dementia, according to government estimates. To qualify for Leqembi, patients must be over 65, have early-stage symptoms and elevated brain amyloid, sticky protein fragments, which the drug is designed to remove.”
